Oral desmopressin acetate (DDAVP®) in the treatment of primary nocturnal enuresis (PNE)

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

An estimated 5.7 million U.S. children 6 years of age or older suffer from primary nocturnal enuresis (PNE), an inability to control overnight bedwetting. Intranasally-administered desmopressin (DDAVP®) has been effectively employed for nearly 10 years in helping to control PNE by decreasing nocturnal urine output to a volume less than the child's functional bladder capacity. A new oral formulation of desmopressin, which is easier and more comfortable to administer, has proven highly effective and safe in controlling overnight bedwetting in both short-term (6-week) and long-term (24-week) clinical trials. Initial therapy begins at a dosage of 200 μg daily, with upward titration to 400 μg or 600 μg/day as needed to achieve an optimal treatment response. The efficacy and safety profile of oral desmopressin makes it the logical first choice of pharmacologic agents available for the treatment of PNE.

Original languageEnglish (US)
Pages (from-to)275-285
Number of pages11
JournalToday's Therapeutic Trends
Volume16
Issue number4
StatePublished - 1998

Fingerprint

Nocturnal Enuresis
Deamino Arginine Vasopressin
Therapeutics
Urinary Bladder
Clinical Trials
Urine
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Oral desmopressin acetate (DDAVP®) in the treatment of primary nocturnal enuresis (PNE). / Skoog, Steven.

In: Today's Therapeutic Trends, Vol. 16, No. 4, 1998, p. 275-285.

Research output: Contribution to journalArticle

@article{11b5935577364baeab0dffa55b0e1f96,
title = "Oral desmopressin acetate (DDAVP{\circledR}) in the treatment of primary nocturnal enuresis (PNE)",
abstract = "An estimated 5.7 million U.S. children 6 years of age or older suffer from primary nocturnal enuresis (PNE), an inability to control overnight bedwetting. Intranasally-administered desmopressin (DDAVP{\circledR}) has been effectively employed for nearly 10 years in helping to control PNE by decreasing nocturnal urine output to a volume less than the child's functional bladder capacity. A new oral formulation of desmopressin, which is easier and more comfortable to administer, has proven highly effective and safe in controlling overnight bedwetting in both short-term (6-week) and long-term (24-week) clinical trials. Initial therapy begins at a dosage of 200 μg daily, with upward titration to 400 μg or 600 μg/day as needed to achieve an optimal treatment response. The efficacy and safety profile of oral desmopressin makes it the logical first choice of pharmacologic agents available for the treatment of PNE.",
author = "Steven Skoog",
year = "1998",
language = "English (US)",
volume = "16",
pages = "275--285",
journal = "Today's Therapeutic Trends",
issn = "0741-2320",
publisher = "Communications Media for Education,Inc",
number = "4",

}

TY - JOUR

T1 - Oral desmopressin acetate (DDAVP®) in the treatment of primary nocturnal enuresis (PNE)

AU - Skoog, Steven

PY - 1998

Y1 - 1998

N2 - An estimated 5.7 million U.S. children 6 years of age or older suffer from primary nocturnal enuresis (PNE), an inability to control overnight bedwetting. Intranasally-administered desmopressin (DDAVP®) has been effectively employed for nearly 10 years in helping to control PNE by decreasing nocturnal urine output to a volume less than the child's functional bladder capacity. A new oral formulation of desmopressin, which is easier and more comfortable to administer, has proven highly effective and safe in controlling overnight bedwetting in both short-term (6-week) and long-term (24-week) clinical trials. Initial therapy begins at a dosage of 200 μg daily, with upward titration to 400 μg or 600 μg/day as needed to achieve an optimal treatment response. The efficacy and safety profile of oral desmopressin makes it the logical first choice of pharmacologic agents available for the treatment of PNE.

AB - An estimated 5.7 million U.S. children 6 years of age or older suffer from primary nocturnal enuresis (PNE), an inability to control overnight bedwetting. Intranasally-administered desmopressin (DDAVP®) has been effectively employed for nearly 10 years in helping to control PNE by decreasing nocturnal urine output to a volume less than the child's functional bladder capacity. A new oral formulation of desmopressin, which is easier and more comfortable to administer, has proven highly effective and safe in controlling overnight bedwetting in both short-term (6-week) and long-term (24-week) clinical trials. Initial therapy begins at a dosage of 200 μg daily, with upward titration to 400 μg or 600 μg/day as needed to achieve an optimal treatment response. The efficacy and safety profile of oral desmopressin makes it the logical first choice of pharmacologic agents available for the treatment of PNE.

UR - http://www.scopus.com/inward/record.url?scp=0032406621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032406621&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 275

EP - 285

JO - Today's Therapeutic Trends

JF - Today's Therapeutic Trends

SN - 0741-2320

IS - 4

ER -